In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphans Should Live Alone

Executive Summary

For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.

Advertisement

Related Content

The Birth Of An Orphan Biosimilar Market
The Birth Of An Orphan Biosimilar Market
Licensing PARP Inhibitor A Win For BioMarin, Medivation
Repurposing Leptin (Part 2): It Really Is A One-In-A-Million Drug
The Orphan Drug Boom: Gold Rush Or Flash In The Pan?
Genentech Reorganization Signals Shift To New Model Under Roche
Shire/TKT: The Price of Diversification

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel